Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bruised Over Humira Patent Games, AbbVie Sees Smoother Road With Botox

Jun 26 2019

• By Cathy Kelly

car on a road in the countryside - Image — Biosimilar Competition For Botox Unlikely In Near Term, AbbVie Says • Source: Shutterstock

Related Content

From Pricing To Patents: Hearing Signals A Potential New Focus

Feb 27 2019

Allergan Shifts Restasis Patents To Native American Tribe To Invoke Immunity From IPR

Sep 09 2017

AbbVie Pounces On Chance To Buy Revenues In $63bn Mega-Deal For Allergan

Jun 25 2019

Another Botox Competitor: Revance Prepares Longer-Lasting RT002 For BLA Submission

Feb 22 2019

Related Companies

AbbVie Inc.

Allergan plc

Revance Therapeutics, Inc.

Viatris Inc.

Additional Topics

United States Pricing Strategies Intellectual Property Biosimilars Policy M & A BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window